Immunovant, a biopharmaceutical company focused on developing innovative therapies for patients living with debilitating autoimmune diseases and currently evaluating IMVT-1401 in patients with moderate-to-severe active
Graves' ophthalmopathy (GO), announced yesterday that it has named Pete Salzmann, MD as its new chief executive officer.
Immunovant recently announced the start of dosing in ASCEND-GO 1, an open label, single-arm Phase 2a clinical trial evaluating IMVT-1401 in patients with moderate-to-severe active
Graves' ophthalmopathy (GO).
Graves' ophthalmopathy is an inflammatory disease of the eye and orbital tissues, and its prevalence has been previously reported to range from 17.1-67.6% in children and adolescents with GD (21,27).
Visual evoked potentials in patients with
Graves' ophthalmopathy complicated by ocular hypertension and suspect glaucoma or dysthyroid optic neuropathy.
In adults, it is commonly related to
Graves' ophthalmopathy, orbital pseudotumor, and rhinosinusitis-related orbital infections.
Multiple sclerosis,
Graves' ophthalmopathy, Miller-Fisher syndrome, mitochondrial diseases, oculopharyngeal muscular dystrophy, vascular causes, and tumors were considered in the differential diagnosis.
Our results were in agreement with Vestergaard20 as he reported that GD patients who smoke had a 5 times higher threat of developing
Graves' ophthalmopathy than those who do not smoke.
Graves' ophthalmopathy is a potentially sight-threatening disease of the orbital cavity, generally accompanied by hyperthyroidism associated with Graves' disease [1].
Tanda et al., "Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe
Graves' ophthalmopathy: results of a prospective, single-blind, randomized study," The Journal of Clinical Endocrinology & Metabolism, vol.
Esser, "Surgical treatment of
Graves' ophthalmopathy," Best Practice and Research Clinical Endocrinology and Metabolism, vol.